Cart
sales@molnova.com
Lexatumumab
CAS No. 845816-02-6
Lexatumumab( —— )
Catalog No. M36731 CAS No. 845816-02-6
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 613 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1387 | In Stock |
|
| 50MG | 1832 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLexatumumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma.
-
DescriptionLexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research.
-
In VitroCell Viability Assay Cell Line:Melanoma cell lines Concentration:0.01, 0.1, 1.0 and 10.0 μg/ml Incubation Time:72 h Result:Induced various degrees of cell death in the different cell lines.
-
In VivoAnimal Model:FEMX-1 xenografts miceDosage:10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection)Administration:i.v., twice a week Result:Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number845816-02-6
-
Formula Weight143.6 (kDa)
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66.?
molnova catalog
related products
-
Examorelin Aceate (1...
Hexarelin?is a growth hormone capable of apoptosis inhibition.
-
Talampanel
Talampanel is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist with anti-seizure activity.
-
Tafasitamab
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.
